Navigation Links
Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation
Date:7/29/2008

s adverse events reported with PBT2.

"These results indicate that PBT2 is having an impact on the underlying biology of Alzheimer's, which is very exciting," Cummings said. "This is a critical proof of concept, and the safety and efficacy demonstrated by PBT2 in this study warrant evaluation in larger scale clinical trials in Alzheimer's."

A Phase IIb trial of a Tau Aggregation Inhibitor Therapy

As an alternative to anti-amyloid therapies for Alzheimer's, researchers continue to examine a variety of treatments and targets with the potential to curb the disease. This includes presenting data supporting the viability of therapies targeting tau protein and its aggregation into the "tangles" originally discovered by Alois Alzheimer.

Previous research has shown that the buildup of brain lesions known as neurofibrillary tangles, which are composed of a short fragment of a protein called tau, is correlated with increasing levels of dementia symptoms. And, these tangles first appear in the brain long before symptoms of the disease become clinically apparent. Methylthioninium chloride (MTC, or brand name rember(TM)) has been shown in the test tube to dissolve tau tangle filaments and prevent aggregation of tau into tangles. MTC has also been shown to block the toxic effects of aggregated tau in cells. In animal models, MTC has demonstrated cognitive and behavioral benefits in line with reduced tau pathology.

In research reported at ICAD 2008, Claude M. Wischik, Professor in Mental Health, University of Aberdeen, United Kingdom and Chairman, TauRx Therapeutics, Singapore, and colleagues conducted a 24-week, double-blind, randomized, dose-ranging, parallel design trial of MTC monotherapy in 321 people with Alzheimer's at 17 centers in the United Kingdom and Singapore, followed by a 60-week, blinded, active treatment extension. The control group received placebo for the initial 24 weeks and then a minimal efficacy dose subsequently. The primar
'/>"/>

SOURCE Alzheimer's Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation
5. Controversy About Lack of Placebo Group Decline in Alzheimers Clinical Trials
6. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
7. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
8. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
9. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
10. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
11. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 Richmond ... research unit with a worldwide reputation for excellence ... frequent publications in peer reviewed medical journals. Its ... and regulators in discussions about rules for transparency ...      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research ...
(Date:5/21/2015)...  When Ryan Rendino first felt the ... neck, he figured it was a muscle ... from weight lifting. But the ... A series of doctor appointments followed ... Michel Kliot, MD , a Northwestern ...
(Date:5/21/2015)... , May 21, 2015  CryoLife, Inc. (NYSE: ... processing company focused on cardiac and vascular surgery, announced ... quarterly cash dividend for the second quarter 2015 of ... cash dividend of $0.03 per share will be paid ... record as of June 12, 2015.  The ex-dividend date ...
Breaking Medicine Technology:Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2
... Calif., Nov. 3 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ... nine months ended September 30, 2009. , For the third ... million, or $0.70 per share, compared to a net loss ... quarter of 2008. Weighted average shares outstanding for the third ...
... operator of a Houston-area durable medical equipment (DME) company ... Assistant Attorney General of the Criminal Division Lanny A. ... of Texas and Daniel R. Levinson, Inspector General of ... Noel Wayne Jhagroo, 47, pleaded guilty to conspiracy to ...
Cached Medicine Technology:Rigel Announces Third Quarter 2009 Financial Results 2Rigel Announces Third Quarter 2009 Financial Results 3Rigel Announces Third Quarter 2009 Financial Results 4Rigel Announces Third Quarter 2009 Financial Results 5Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 2Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 3
(Date:5/23/2015)... 2015 With the implementation of the ... it increasingly difficult to provide their employees with a ... adequate insurance for employees stand to face strict penalties. ... integral part of a business’s success or failure. In ... Online USA Doctors has created a varying level of ...
(Date:5/23/2015)... 23, 2015 Javon Bea Mercy ... Sports Medicine and Rehabilitation Center, 557 N. Washington St., ... June 1-July 20, 5:30-6:30 pm. , The 8-week clinic ... Laurie Finke, RN, BSN, who will offer training that ... nutrition, running mechanics and show selection and weekly training ...
(Date:5/22/2015)... 2015 The American College of Traditional ... June. They will hold a webinar on the updates ... class on Classical Chinese Medicine. , Webinar – First ... Given, the Dean of Clinical Education, will lead this ... Professional Doctorate program. ACTCM is currently developing this degree ...
(Date:5/22/2015)... May 22, 2015 Omar Ahmad Barrada, ... to participate in the 2015 Congress of Future Medical ... as a gathering of “America’s highest achieving high school ... of healthcare, set new goals and learn better study ... live surgery, during which we can ask the surgeons ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Carnegie ... today announced a new partnership to develop BodyTech, ... the region. The initiative includes a new exhibit at ... live demonstration theater, and a new traveling science show, ... fall of 2015. , Designed to explore a ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
... SPOKANE, Wash., May 7 MIPSolutions, Inc. (OTC,Bulletin ... the,University of Utah has revealed a significant development ... that Molecularly Imprinted,Ionomer (MII) beads imprinted to retain ... This translates into decreased development,time, a large amount ...
... May 7 Amneal Pharmaceuticals is pleased,to announce ... Primidone,Tablets (50/250mg), Cyclobenzaprine Tablets (10mg) and Demeclocycline,Tablets (150/300mg) ... products,were filed during 2007 using the FDA,s evolutionary ... months., Demeclocycline HCl Tablets USP, in strengths ...
... Inc. is offering any,expectant mom free prenatal prescription vitamins ... company announced,today., Just in time for Mother,s Day, ... to all expectant mothers for a full year,which includes ... Save store in North Texas. This is the first ...
... other hospital and healthcare advocates from across the,state will ... the nearly $300,million in healthcare cuts proposed in Gov. ... Tomorrow," a Rally to Preserve Our Healthcare, WHERE: ... 12 noon, May 12, The "Care Today, Gone ...
... May 7 GlaxoSmithKline (GSK) Consumer,Healthcare, marketer of ... CQ(R) patch, and Commit(R) lozenge, applauds,the release of ... Guideline,on Treating Tobacco Use and Dependence. Too many ... cold turkey approaches to become,tobacco-free. The Guideline is ...
... 7 Vaccinogen Inc. said Dutch health,authorities licensed it ... the path to more than $100 million of,potential European ... based in Emmen, The,Netherlands also paves the way to ... final step before the vaccine can be sold in ...
Cached Medicine News:Health News:MIPSolutions, Inc. Reduces Expense and Development Time Associated With Precious Metal Extraction 2Health News:Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format 2Health News:Expectant Moms Offered Free Prenatal Prescription Vitamins at D-FW Area Carnival, Minyard and Sack'n Save Stores 2Health News:A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence 2Health News:A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence 3Health News:Dutch Authorize Manufacture of Vaccinogen's New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial 2
Lumenis offers you the latest non-invasive system for Intense Pulsed Light (IPL) skin treatments using proprietary broad spectrum IPL technology....
... The new IPL Quantum DL system ... with the reliability and simplicity expected ... modular and upgradeable design protects your ... SR mode for IPL skin treatments ...
The playful pattern of this lens features sky-blue forms fanning out from the center of your eye....
The opaque outer circle will white-out even the darkest iris, making your pupil the only spot of black in a sea of white....
Medicine Products: